As of November 6, 2025 Building a Between-Visit Provider Our Mission Bend the curve Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions, and other factors. Because forward-looking statements relate to the future, they are subject to inhere ...

Core Insights - Medtronic plc is a global leader in healthcare technology, focusing on device-based medical therapies and services for various health conditions [1] Financial Performance - Medtronic is set to report its Q2 2026 earnings on November 18, with analysts expecting an EPS of $1.31, an increase from $1.26 in the previous year [2] - Quarterly revenue is anticipated to reach $8.85 billion, up from $8.40 billion a year earlier [2] - The company reported Q1 2026 earnings with an adjusted EPS of $1.26, exceeding the consensus estimate of $1.23, and revenues of $8.58 billion, surpassing the consensus of $8.38 billion [3] Growth Outlook - The CEO highlighted a consistent quarter of mid-single-digit organic revenue growth, driven by innovative product categories such as Pulsed Field Ablation and Transcatheter Valves [4] - Medtronic raised its full-year 2026 diluted non-GAAP EPS guidance to a new range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60 [4] Dividend Information - Medtronic's dividend yield stands at 2.98%, with a total dividend payout of $2.84 per share over the last 12 months [2] - To generate an income of $100 per month from dividends, an investment of approximately $40,268 is required, based on the current dividend yield [5][6]

Core Insights - Medtronic plc reported its first quarter fiscal 2026 financial results, achieving mid-single digit organic revenue growth for the 11th consecutive quarter, with expectations to accelerate growth in the second half of the fiscal year [1][2][3] Financial Performance - The company reported worldwide revenue of $8.578 billion, an increase of 8.4% as reported and 4.8% on an organic basis [3][4] - GAAP operating profit was $1.445 billion with an operating margin of 16.8%, reflecting a 13% increase and a 70 basis point improvement [3][4] - Non-GAAP operating profit was $2.016 billion with a margin of 23.6%, showing a 3% increase but an 80 basis point decrease [3][4] Earnings and Guidance - GAAP net income was $1.040 billion, with diluted earnings per share (EPS) at $0.81, remaining flat, while non-GAAP diluted EPS increased by 2% to $1.26 [4][8] - The company raised its FY26 EPS guidance to a range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60, and reiterated its organic revenue growth guidance of approximately 5% [7][8][9] Segment Performance - Cardiac Ablation Solutions revenue surged nearly 50%, with a 72% increase in the U.S. driven by pulsed field ablation products [4][5] - The Cardiovascular Portfolio generated $3.285 billion in revenue, a 9.3% increase as reported and 7.0% organic [5][19] - The Diabetes business reported revenue of $721 million, an increase of 11.5% as reported and 7.9% organic [5][19] International and U.S. Revenue - International revenue reached $4.354 billion, a 13.6% increase, while U.S. revenue was $4.224 billion, reflecting a 3.5% increase [22][19] - The Cardiovascular segment in the international market grew by 12.6%, with notable increases in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic categories [22][19] Operational Efficiency - The company is focused on improving efficiencies in manufacturing, supply chain, and operating expenses to drive earnings growth while increasing investments in R&D, sales, and marketing [9][8]

Core Insights - Medtronic reported strong financial results for Q4 and FY25, with notable growth in key franchises such as Pulsed Field Ablation, TAVR, and Diabetes [1][3][12] Q4 Financial Results - Q4 worldwide revenue reached $8.927 billion, marking a 3.9% increase as reported and 5.4% on an organic basis [6][7] - Q4 GAAP operating profit was $1.436 billion, a 36% increase, with an operating margin of 16.1%, up 380 basis points [6][7] - Non-GAAP diluted EPS for Q4 was $1.62, an 11% increase, while GAAP diluted EPS was $0.82, up 67% [7][8] FY25 Financial Results - FY25 worldwide revenue totaled $33.537 billion, a 3.6% increase as reported and 4.9% on an organic basis [9][10] - FY25 GAAP operating profit was $5.955 billion, a 16% increase, with an operating margin of 17.8%, up 190 basis points [9][10] - Non-GAAP diluted EPS for FY25 was $5.49, a 6% increase, while GAAP diluted EPS was $3.61, up 31% [10] Key Business Segments - The Cardiovascular Portfolio generated FY25 revenue of $12.481 billion, a 5.5% increase as reported and 6.3% organic [13] - The Neuroscience Portfolio reported FY25 revenue of $9.846 billion, a 4.7% increase reported and 5.2% organic [14] - The Medical Surgical Portfolio had FY25 revenue of $8.407 billion, showing a slight decrease of 0.1% reported but an increase of 0.8% organic [15] Diabetes Business Separation - Medtronic announced plans to separate its Diabetes business into a standalone public company, expected to be completed within 18 months [19] Dividend Increase - The company declared a dividend increase to $0.71 per share for Q1 FY26, marking the 48th consecutive year of dividend increases [22] Guidance for FY26 - Medtronic anticipates FY26 organic revenue growth of approximately 5%, with diluted non-GAAP EPS growth expected to be around 4% [23][24]